Table 3

Comparison between active and inactive disease in different organ systems

Kidney*Joints†Skin/mucosa‡
Inactive
(n=363)
BILAG=
C/D/E
Active
(n=42)
BILAG=
A/B
P value§Inactive
(n=356)
SLAM 24≤1
Active
(n=74)
SLAM 24≥2
P value§Inactive
(n=317)
SLAM4+6=0
Active
(n=109)
SLAM4+6 ≥1
P value§
Cytokines¶
 INF-γ11.5
(6.9–19.3)
18.5
(7.4–44.0)
0.0311.5
(6.8–19.5)
12.3
(7.6–28.2)
0.210.9
(6.7–19.6)
13.0
(7.2–19.7)
0.09
 IL-84.9
(3.1–8.4)
5.6
(3.2–13.6)
0.24.8
(3.0–8.4)
5.2
(3.4–10.1)
0.24.8
(3.0–8.2)
5.0
(3.3–9.8)
0.3
 IL-152.9
(2.3–3.8)
4.2
(2.6–5.7)
0.00072.9
(2.3–4.1)
3.0
(2.4–4.0)
0.62.9
(2.3–4.1)
3.1
(2.4–3.9)
0.5
 Eotaxin132.6
(96.6–188.5)
144.1
(91.6–183.7)
0.6133.5
(96.7–185.9)
129.2
(98.1–182.2)
0.9131.8
(99.7–185.7)
134.8
(94.8–188.4)
0.7
 MCP-1105.2
(82.2–148.8)
137.5
(96.2–200.3)
0.007106.7
(83.1–148.2)
119.2
(83.1–172.0)
0.2108.8
(83.4–150.1)
111.0
(81.1–183.4)
0.6
 MDC880.9
(670.3–1136.0)
677.0
(507.6–969.0)
0.002843.9
(647.2–1117.3)
814.4
(584.1–1135.0)
0.5838.5
(623.0–1111.4)
886.7
(662.8–1173.5)
0.3
 MIP-1β68.9
(50.6–102.8)
94.6
(54.7–122.9)
0.0569.7
(50.5–105.6)
79.3
(54.4–125.0)
0.173.8
(50.4–109.7)
67.0
(51.2–106.8)
0.6
 IL-100.78
(0.50–1.38)
1.07
(0.83–3.38)
0.0020.79
(0.49–1.40)
1.04
(0.64–1.93)
0.040.85
(0.51–1.42)
0.81
(0.52–1.78)
0.6
 IL-61.09
(0.64–1.95)
1.96
(1.08–4.00)
0.00041.10
(0.66–2.01)
1.49
(0.82–3.30)
0.0061.10
(0.67–2.07
1.34
(0.68–2.29)
0.4
 TNF-α4.2
(3.0–5.8)
6.5
(5.5–10.9)
6.4×10–94.4
(3.1–5.9)
5.6
(3.5–7.9)
0.0064.4
(3.1–6.1)
4.6
(3.1–6.4)
0.4
 IL-12/IL-23p40172.0
(120.4–279.0)
214.6
(145.0–405.5)
0.01178.9
(122.9–279.3)
196.7
(112.8–369.5)
0.2180.4
(127.7–284.9)
185.9
(111.4–294.9)
0.7
 IL-16194.8
(145.4–259.6)
308.7
(228.2–413.6)
1.7×10–7208.6
(149.3–275.3)
235.7
(154.5–366.7)
0.04216.6
(156.1–292.4)
186.0
(137.9–269.4)
0.03
 IL-1α6.1
(3.1–12.2)
8.4
(4.5–21.7)
0.045.6
(3.2–12.4)
9.0
(3.9–18.9)
0.0056.4
(3.3–14.4)
5.3
(3.1–11.8)
0.5
 IL-75.0
(3.1–8.5)
6.8
(4.4–9.2)
0.165.0
(3.0–8.8)
5.1
(3.2–8.1)
0.75.0
(3.0–8.7)
5.0
(3.2–8.4)
0.7
 VEGF74.8
(47.8–119.7)
86.1
(46.2–146.1)
0.2773.2
(47.1–118.0)
91.4
(55.4–157.4)
0.04674.1
(47.9–112.9)
81.6
(45.5–155.4)
0.5
 Eotaxin-324.4
(19.3–34.2)
31.2
(19.0–35.4)
0.824.4
(19.4–34.9)
24.7
(19.1–34.6)
0.924.2
(19.4–35.6)
25.0
(18.9–34.6)
1.0
 IP-10739.6
(458.8–1459.5)
1205.3
(393.5–2428.9)
0.4700.8
(426.5–1311.3)
940.0
(605.3–2566.7)
0.0005705.2
(416.1–1370.6)
855.7
(529.2–2123.0)
0.003
 MCP-479.8
(54.4–129.3)
70.4
(48.3–95.3)
0.0476.5
(53.2–122.4)
79.9
(53.8–126.2)
0.475.4
(53.6–119.3)
79.0
(51.9–129.0)
0.8
 MIP-1α20.3
(17.0–26.9)
29.5
(21.4–37.4)
0.000921.0
(17.1–27.2)
23.9
(17.8–32.0)
0.0821.8
(17.3–30.8)
21.4
(17.2–24.9)
0.2
 TARC87.0
(53.3–151.0)
74.0
(41.0–132.1)
0.286.7
(51.3–153.0)
82.3
(55.9–131.6)
0.978.0
(51.2–138.7)
96.1
(54.4–160.1)
0.1
Standard clinical laboratory measurements¶
 ESR18
(10–32)
30
(14–67)
0.000118
(10–32)
29
(13.2–38.8)
0.00618
(10–33)
22
(13–39)
0.08
 C40.15
(0.11–0.20)
0.13
(0.06–0.18)
0.050.15
(0.11–0.20)
0.13
(0.07–0.18)
0.020.15
(0.10–0.20)
0.15
(0.10–0.19)
0.6
 C30.89
(0.74–1.05)
0.74
(0.55–0.87)
0.00050.88
(0.72–1.05)
0.82
(0.62–1.04)
0.10.88
(0.71–1.04)
0.87
(0.74–1.05)
0.8
 P-albumin39
(37–42)
31
(26–31)
4.2×10–1639
(36–42)
38
(34–41)
0.0839
(36–42)
39
(35–41)
0.3
 hsCRP1.5
(0.6–4.7)
2.2
(1.1–8.9)
0.011.6
(0.6–4.9)
2.9
(0.8–7.4)
0.0471.6
(0.6–4.9)
1.7
(0.8–6.2)
0.3
 Anti-dsDNA4
(4–16)
22
(5–89)
2.2×10–65
(4–17)
7
(4–49)
0.025
(4–18)
5
(4–26)
0.6
 U-albumin/creatinine0.8
(0.5–2.3)
75.4
(46.6–834.9)
1.0×10–231.0
(0.5–5)
1.5
(0.7–12.2)
0.21.1
(0.5–6.7)
1.1
(0.5–4.9)
0.5
  • *Renal BILAG A/B as measure of kidney involvement (active, n=42) vs renal BILAG=C/D/E as a measure of patients without active kidney involvement (n=363).

  • †Patients with SLAM item 24>1 (n=74) were defined as patients with joint involvement (active) and patients with SLAM item 24≤1 (n=356) were defined as patients with inactive joint involvement.

  • ‡Skin/mucosal involvement if SLAM 4+SLAM 6>0 (active, n=109). No skin/mucosal involvement if SLAM 4+6 = 1 (n=317).

  • §P values (Mann-Whitney U-test) are reported and highlighted in bold if significant after Bonferroni correction for multiple testing.

  • ¶Median (25% quantile–75% quantile). Concentrations of cytokines are reported in pg/mL. Standard clinical laboratory measurements reported as ESR in mm/hour, Complement factor C4 in g/L, Complement factor C3 in g/L, plasma albumin (p-albumin) in g/L, high-sensitivity (hs) CRP in mg/L, anti-dsDNA units and urinary (u) albumin/creatinine ratio in mg/mmol.

  • BILAG, British Isles Lupus Assessment Group, Renal index; ESR, erythrocyte sedimentation rate; SLAM, SLE Activity Measure; SLE, systemic lupus erythematosus.